Kangstem Biotech Applies for Phase 3 Clinical Trial of PureSystem-AD Injection for Chronic Atopic Dermatitis
[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 29th that it has applied to the Ministry of Food and Drug Safety (MFDS) for a Phase 3 clinical trial to evaluate the efficacy and safety of PureSystem-AD injection in patients with moderate to severe chronic atopic dermatitis.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- No Cure in Sight... '105 Deaths' Spark Fears as American Also Infected
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
- "SEC Set to Capture Semiconductor, Defense, and Battery Markets... Benefiting from Localization of X-ray Inspection Equipment" [Click e-Stock]
- [Breaking] Chung Yongjin Apologizes for Starbucks 'Tank Day' Controversy: "I Take Full Responsibility"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
